Progressive Care (OTCQB: RXMD), a personalized healthcare services and technology provider, has announced its successful completion of a transaction of $1 million investment from NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider. In connection with the $1 million investment, the company sold to NextPlat 455,000 newly issued units, with each comprised of one share of the company’s common stock and one warrant to purchase a share of common stock and a per-unit purchase price of $2.20. In addition, Charles M. Fernandez, who serves as chairman and CEO of both Progressive Care and NextPlat, Rodney Barreto, vice chairman of Progressive Care and director of the board of NextPlat, and certain other Progressive Care convertible note holders, agreed to convert the approximately $2.9 million of outstanding principal and accrued and unpaid interest under the note to shares of Progressive Care’s common stock at a conversion price of $2.20 per share. Dawson James Securities Inc. served as an advisor for the transaction. Lucosky Brookman, New York, NY, acted as counsel to the company and ArentFox Schiff LLP, Washington, D.C., served as counsel to NextPlat.

To view the full press release, visit https://ibn.fm/RXKtT

About Progressive Care Inc.

Progressive Care, through its subsidiaries, is a Florida health services organization and provider of third-party administration (“TPA”), data management, COVID-19 related diagnostics and vaccinations, 340B contracted pharmacy services, prescription pharmaceuticals, compounded medications, tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (“MTM”), the supply of prescription medications to long-term care facilities, and health practice risk management.

NOTE TO INVESTORS: The latest news and updates relating to RXMD are available in the company’s newsroom at https://ibn.fm/RXMD

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork